Cargando…
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
There are currently seven approved immune checkpoint inhibitors (ICIs) for the treatment of various cancers. These drugs are associated with profound, durable responses in a subset of patients with advanced cancers. Unfortunately, in addition to individuals whose tumors show resistance, there is a m...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011624/ https://www.ncbi.nlm.nih.gov/pubmed/32043794 http://dx.doi.org/10.1634/theoncologist.2019-0636 |